EAST NORRITON, Pa., July 7 /PRNewswire-FirstCall/ — Tengion
Inc. (Nasdaq: TNGN) today announced that it has appointed Sunita B. Sheth, M.D., to the position of
Chief Medical Officer, Vice President, Clinical and Regulatory
Affairs. In this role, Dr. Sheth will be responsible for developing
clinical development strategies, implementing clinical trials, and
providing clinical translation insights to preclinical pipeline
programs.
“We are extremely pleased to add Dr. Sheth to the Tengion team,”
stated Steven Nichtberger, M.D.,
President and Chief Executive Officer of Tengion. “Her broad
experience in multiple therapeutic areas, deep knowledge of early
and late stage clinical development, and commitment to patient care
will be invaluable to Tengion as we continue to advance our
platform and product candidates.”
Dr. Sheth most recently served as Vice President, Specialty Care
Business Unit, for Pfizer as part of its acquisition of Wyeth.
Prior to that, she spent four years at Wyeth, most recently as Vice
President, Cardiovascular, Metabolic and Infectious Diseases.
Before joining Wyeth, she held positions of increasing
responsibility at AstraZeneca and GlaxoSmithKline since joining the
industry in 1997. Her pharmaceutical development leadership
experience covers multiple therapeutic areas and phases of
development including approval of several INDs for drugs as well as
the biologics FIX mab and OAP-189; the global regulatory submission
of ximelagatran for multiple indications; and approval of an sNDA
for Tygacil.
“This is an exciting time for Tengion and I am very much looking
forward to working closely with the man
‘/>”/>
SOURCE
